Lupin Stock Screener | Share Price & Fundamental Analysis
LUPIN
Pharmaceuticals
Screen Lupin share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹2149.70
▲
66.00 (3.17%)
Share Price BSE
₹2151.95
▲
73.75 (3.55%)
Market Cap
₹95,964.29 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
4.91
EPS (TTM)
₹71.95
Dividend Yield
0.57%
Debt to Equity
0.27
52W High
₹2252.85
52W Low
₹1851.80
Operating Margin
31.00%
Profit Margin
21.46%
Revenue (TTM)
₹6,921.00
EBITDA
₹2,215.00
Net Income
₹1,485.00
Total Assets
₹29,205.00
Total Equity
₹17,294.00
Lupin Share Price History - Stock Screener Chart
Screen LUPIN historical share price movements with interactive charts. Analyze price trends and patterns.
Lupin Company Profile - Fundamental Screener
Screen Lupin company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for LUPIN shares.
Lupin is a global pharmaceutical company producing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Founded in 1983, it operates in over 100 markets, specializing in cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal, anti-infective, and NSAID therapies. Lupin is a leader in anti-TB and cephalosporins segments. The company has expanded through acquisitions and partnerships, entering markets in Japan, Germany, Australia, South Africa, and the Philippines. Lupin has manufacturing facilities in various locations and has received FDA approvals for multiple generic drugs. The company has also launched innovative products and entered strategic alliances with other pharmaceutical companies for drug development and marketing.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
M D Gupta
ISIN
INE326A01037
Website
https://www.lupin.com/
Lupin Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen LUPIN balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 29,205 | 23,997 | 22,956 | 21,821 | 23,610 | 24,984 | 27,949 | 26,305 | 26,607 | 22,625 |
| Current Assets | 16,799 | 13,448 | 12,451 | 12,458 | 13,986 | 15,413 | 13,854 | 12,210 | 11,953 | 9,887 |
| Fixed Assets | 9,719 | 8,878 | 8,355 | 7,382 | 7,881 | 7,938 | 11,087 | 10,362 | 11,033 | 8,717 |
| Liabilities | ||||||||||
| Total Liabilities | 29,205 | 23,997 | 22,956 | 21,821 | 23,610 | 24,984 | 27,949 | 26,305 | 26,607 | 22,625 |
| Current Liabilities | 2,949 | 1,122 | 1,148 | 1,101 | 1,316 | 3,178 | 8,030 | 7,593 | 6,955 | 6,368 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 17,294 | 14,374 | 12,543 | 12,222 | 13,858 | 12,581 | 13,789 | 13,617 | 13,532 | 11,196 |
| Share Capital | 91 | 91 | 91 | 91 | 91 | 91 | 91 | 90 | 90 | 90 |
| Reserves & Surplus | 17,112 | 14,199 | 12,374 | 12,062 | 13,712 | 12,446 | 13,652 | 13,487 | 13,407 | 11,073 |
Screen LUPIN income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6,921 | 6,243 | 5,619 | 5,672 | 5,539 | 5,582 | 4,924 | 4,368 | 4,765 | 4,980 | 5,109 | 3,880 | 3,610 | 4,106 | 4,263 |
| Expenses | 4,706 | 4,541 | 4,346 | 4,412 | 4,332 | 4,359 | 3,964 | 3,852 | 3,958 | 4,121 | 4,160 | 3,615 | 3,512 | 3,693 | 3,790 |
| EBITDA | 2,215 | 1,702 | 1,273 | 1,261 | 1,207 | 1,223 | 960 | 515 | 807 | 859 | 950 | 265 | 98 | 414 | 473 |
| Operating Profit % | 31.00% | 26.00% | 22.00% | 21.00% | 21.00% | 21.00% | 19.00% | 11.00% | 17.00% | 17.00% | 18.00% | 6.00% | 3.00% | 10.00% | 11.00% |
| Depreciation | 317 | 299 | 393 | 272 | 257 | 248 | 457 | 264 | 235 | 248 | 257 | 327 | 193 | 204 | 220 |
| Interest | 108 | 92 | 89 | 67 | 71 | 68 | 71 | 93 | 86 | 81 | 74 | 42 | 43 | 55 | 84 |
| Profit Before Tax | 2,007 | 1,416 | 896 | 1,071 | 1,055 | 993 | 498 | 259 | 559 | 630 | 736 | -85 | 2 | 210 | 246 |
| Tax | 522 | 194 | 114 | 212 | 195 | 188 | 130 | 16 | 106 | 134 | 117 | 427 | 89 | 75 | 89 |
| Net Profit | 1,485 | 1,222 | 782 | 859 | 860 | 806 | 368 | 242 | 453 | 495 | 619 | -512 | -87 | 135 | 158 |
| EPS | 32.36 | 26.70 | 16.93 | 18.75 | 18.70 | 17.58 | 7.89 | 5.19 | 9.94 | 10.76 | 13.47 | -11.40 | -1.96 | 2.85 | 3.38 |
Lupin Cash Flow Screener - Liquidity Fundamentals
Screen LUPIN cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 3,000 | 3,648 | 1,897 | 367 | 1,822 | 1,469 | 1,666 | 1,751 | 4,114 | -382 |
| Investing Activities | -4,172 | -1,712 | -1,287 | 1,292 | -1,240 | 1,107 | -3,283 | 470 | -2,527 | -6,769 |
| Financing Activities | 1,732 | -2,184 | -337 | -1,572 | -1,885 | -891 | 744 | -1,492 | 433 | 5,836 |
| Net Cash Flow | 560 | -248 | 273 | 87 | -1,303 | 1,685 | -872 | 729 | 2,019 | -1,315 |
Screen LUPIN shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 46.90% | 46.90% | 46.92% | 46.95% | 46.96% | 46.98% | 47.01% | 47.04% |
| FII Holding | 20.49% | 21.25% | 21.46% | 22.04% | 21.50% | 19.32% | 18.28% | 16.11% |
| DII Holding | 26.55% | 25.56% | 25.41% | 24.74% | 25.09% | 26.78% | 27.76% | 29.73% |
| Govt Holding | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public Holding | 5.12% | 5.23% | 5.10% | 5.17% | 5.29% | 5.65% | 5.70% | 5.87% |
| Other Holding | 0.94% | 1.05% | 1.10% | 1.10% | 1.15% | 1.26% | 1.23% | 1.23% |
| Shareholder Count | 280,256 | 286,604 | 283,210 | 281,988 | 279,280 | 288,537 | 280,248 | 281,542 |
Lupin Dividend Screener - Share Yield Analysis
Screen LUPIN dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹12.00 | 0.57% |
| 2024-March | ₹8.00 | 0.39% |
| 2023-March | ₹4.00 | 0.25% |
| 2022-March | ₹4.00 | 0.61% |
| 2021-March | ₹6.50 | 0.87% |
| 2020-March | ₹6.00 | 0.59% |
| 2019-March | ₹5.00 | 0.85% |
| 2018-March | ₹5.00 | 0.68% |
| 2017-March | ₹7.50 | 1.02% |
Lupin Index Membership - Market Screener Classification
Screen LUPIN by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Lupin Market Events Screener - Corporate Actions
Screen LUPIN market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | 2.76% |
| 2025-08-11 | 2025-08-11 | Annual General Meeting | NA | 1.23% |
| 2025-08-05 | 2025-08-05 | Quarterly Result Announcement | NA | -2.52% |
| 2025-07-25 | 2025-07-25 | Dividend | ₹ 12.00 /share | -5.80% |
| 2025-05-14 | 2025-05-14 | Quarterly Result Announcement | NA | -2.12% |
| 2025-02-11 | 2025-02-11 | Quarterly Result Announcement | NA | 1.65% |
| 2024-11-07 | 2024-11-07 | Quarterly Result Announcement | NA | 0.66% |
| 2024-08-02 | 2024-08-02 | Annual General Meeting | NA | 9.82% |
| 2024-07-16 | 2024-07-16 | Dividend | ₹ 8.00 /share | 10.68% |
| 2023-07-14 | 2023-07-14 | Dividend | ₹ 4.00 /share | 27.11% |
| 2022-07-14 | 2022-07-15 | Dividend | ₹ 4.00 /share | -5.87% |
| 2021-07-27 | 2021-07-28 | Dividend | ₹ 6.50 /share | -8.30% |
Lupin Competitors Screener - Peer Comparison
Screen LUPIN competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,038 | 39.35 | 54,729 | 9.71% | 10,980 | 38.94 |
| Divis Laboratories | 167,550 | 68.31 | 9,712 | 18.67% | 2,191 | 47.61 |
| Torrent Pharmaceuticals | 129,963 | 60.76 | 11,539 | 6.99% | 1,911 | 63.27 |
| Cipla | 121,150 | 22.46 | 28,410 | 7.12% | 5,291 | 50.85 |
| Dr Reddys Laboratories | 104,371 | 18.49 | 33,741 | 16.73% | 5,725 | 53.02 |
| Lupin | 95,964 | 22.19 | 22,910 | 13.74% | 3,306 | 57.47 |
| Zydus Life Science | 91,884 | 18.30 | 23,511 | 18.55% | 4,615 | 43.59 |
| Mankind Pharma | 89,542 | 51.11 | 12,744 | 20.90% | 2,007 | 49.10 |
| Aurobindo Pharma | 68,784 | 20.05 | 32,346 | 9.43% | 3,484 | 45.26 |
| Alkem Laboratories | 65,282 | 27.31 | 13,458 | 3.70% | 2,216 | 41.76 |
Lupin Company Announcements - News Screener
Screen LUPIN latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-06 | Announcement under Regulation 30 (LODR)-Updates on Acquisition | View |
| 2026-01-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2026-01-02 | Closure of Trading Window | View |
| 2025-12-18 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-17 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-16 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-16 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-12 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-11 | Newspaper Publication For The Information Regarding Special Window For Re-Lodgement For Transfer Request Of Physical Shares. | View |
| 2025-12-10 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2025-12-09 | ESG Rating By NSE Sustainability Ratings & Analytics Limited. | View |
| 2025-12-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-04 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-01 | Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised) | View |
| 2025-11-28 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-21 | U.S. FDA Has Conducted An Inspection At Companys Manufacturing Facility Located At Goa India. | View |
| 2025-11-15 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |